The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR?) early breast cancer. We investigated the prognostic and predictive value of centrally assessed levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 expression in women with HER2-negative disease. Of 5707 women enrolled, 4115 with HER2-negative (HR?/HER2-) disease had ER, PgR, and Ki-67 centrally assessed by immunohistochemistry. Breast cancer-free interval (BCFI) was defined from randomization to first invasive local, regional, or distant recurrence or contralateral breast cancer. The prognostic and predictive values of ER, PgR and Ki-67 expression levels were assessed using Cox modeling and STEPP methodology. In this HR?/HER2-population, the median ER, PgR, and Ki-67 expressions were 95, 90, and 18 % immunostained cells. As most patients had strongly ER-positive tumors, the predictive value of ER levels could not be investigated. Lower PgR and higher Ki-67 expression were associated with reduced BCFI. There was no consistent evidence of heterogeneity of the relative treatment effects according to PgR or Ki-67 expression levels, though there was a greater 5-year absolute benefit of exemestane ? ovarian function suppression (OFS) versus 
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Introduction
Two international randomized phase III trials, Tamoxifen and Exemestane Trial (TEXT) and Suppression of Ovarian Function Trial (SOFT), recently reported results evaluating three adjuvant endocrine therapy regimens for premenopausal women with endocrine-responsive early breast cancer [1] [2] [3] . The trials demonstrated that 5 years of adjuvant treatment with the aromatase inhibitor (AI) exemestane, in combination with ovarian function suppression (OFS), improved outcomes relative to tamoxifen plus OFS or to tamoxifen alone; and that tamoxifen plus OFS improves outcomes relative to tamoxifen alone in women who were at sufficient risk to warrant adjuvant chemotherapy and remained premenopausal thereafter [2, 3] . SOFT further indicated that tamoxifen alone remains an appropriate option for some premenopausal women at low risk of recurrence [3] . In postmenopausal women randomized in the Breast International Group (BIG) 1-98 trial to receive 5 years of tamoxifen or the AI letrozole, as monotherapy or in sequence, very high levels of tumor Ki-67 expression were an adverse prognostic factor and also suggested predictive value for greater benefit of letrozole versus tamoxifen [4] , but levels of estrogen receptor (ER) and progesterone receptor (PgR) expression were not predictive markers for treatment selection [5] . To help selection among three endocrine therapy options for premenopausal women with HER2-negative disease, we investigated the predictive value and absolute magnitude of treatment benefits according to levels of tumor ER, PgR, and Ki-67 expressions assessed by central pathology review. Although PgR level is not predictive of differential benefit of an AI versus tamoxifen in postmenopausal women, we hypothesized that the situation would be different for premenopausal women and that lower levels of PgR would predict for greater effects of endocrine therapy regimens. We postulated that very high Ki-67 would predict for the greatest benefit of exemestane plus OFS relative to tamoxifen, with or without OFS. The HER2-positive population, for whom trastuzumab is also given as adjuvant therapy, will be the subject of a separate investigation.
Methods

Study designs
The designs and conduct of the trials have been described previously [1] [2] [3] ; the ethics committees and required health authorities of each participating center approved the trial protocols, and all patients gave written informed consent. In both trials, eligible premenopausal women had early invasive breast cancer assessed as ER and/or PgR expressing in C10 % of cells by local determination.
TEXT was designed to determine the role of adjuvant therapy with the AI exemestane relative to tamoxifen in premenopausal women treated with OFS from the start of adjuvant therapy. Between November 2003 and March 2011, 2672 eligible women were randomized 1:1 to 5 years of exemestane ? OFS or 5 years of tamoxifen ? OFS. OFS was by gonadotropin-releasing hormone (GnRH) agonist triptorelin, bilateral oophorectomy, or bilateral ovarian irradiation. Chemotherapy was optional, and if administered, was started concurrently with triptorelin. Randomization was stratified according to the intended use of adjuvant chemotherapy and lymph-node status.
SOFT was designed to determine the value of adding OFS to tamoxifen, and to determine the role of exemestane ? OFS in two cohorts of premenopausal women, those who remained premenopausal after completion of (neo)adjuvant chemotherapy, and those for whom adjuvant tamoxifen alone was considered suitable treatment. Between December 2003 and January 2011, 3066 eligible women were randomized 1:1:1 to 5 years of exemestane ? OFS or tamoxifen ? OFS or tamoxifen alone. Randomization was stratified according to use of prior chemotherapy, lymph-node status, and intended initial method of OFS (if randomly assigned to OFS).
Central pathology review
Tumor tissue was prospectively collected, and the patients were consented for protocol-mandated central review of histopathologic features and expressions of ER, PgR, HER2, and Ki-67 labeling index (hereafter, Ki-67). IBCSG Central Pathology Office performed central review of whole sections obtained from formalin-fixed paraffin-embedded (FFPE) primary tumor specimens, including assessment of tumor type and grade, and immunohistochemical (IHC) evaluation of ER, PgR, and Ki-67. If submitted material was limited, then testing was prioritized for ER, PgR, HER2, and then Ki-67. All the immunoreactions were performed with an automated immunostainer (Austostainer, Dako, DK) using the ER/PgR PharmDX kit (Dako, Glostrup, DK) according to the manufacturer's instructions for hormone receptors, and the MIB1 monoclonal antibody (Dako) for Ki-67, as previously reported [4] . The results were recorded as the percentage of immunostained cells. HER2 expression was evaluated with the HercepTest kit (Dako) and scored as 0, 1?, 2?, or 3?, according to the FDA scoring system. Tumors scored as 2? were re-tested with fluorescent in situ hybridization (FISH) using the PathVysion HER2 DNA probe kit (Vysis-Abbott, Chicago, IL, USA). To ensure the intraobserver and interobserver reliability of the central assessment, 5 % of the centrally evaluated tumors were blindly reassessed by the same pathologist and 10 % by a different pathologist. If the recorded percentages of immunostained cells differed by more than 10 %, then a collegial reevaluation at the multiheaded microscope was performed. Pathology assessment was done without the knowledge of patients' treatment assignments or outcomes.
Tumors were considered as centrally confirmed to be ER or PgR expressing when C1 % invasive tumor cells showed definite nuclear staining, irrespective of staining intensity [6] . Tumors were considered as HER2-positive if the IHC score was 3? or FISH showed a HER2-to-chromosome 17 ratio of C2.0.
Analysis population, endpoint, and statistical considerations
The analysis population included patients in the intentionto-treat trial populations for whom the IBCSG Central Pathology Office reviewed invasive tumor material. Although trial eligibility required C10 % cells staining for ER and/or PgR on local testing, for this analysis population, only patients whose submitted tumor was not confirmed to express any ER or PgR by central testing were excluded. Patients for whom tumor was assessed centrally or locally as HER2-positive were also excluded. The study endpoint was breast cancer-free interval (BCFI), defined as time from randomization to first appearance of invasive breast cancer recurrence (local, regional, or distant) or invasive contralateral breast cancer; in the absence of an event, time was censored at date of last follow-up. The associations of pre-defined marker subgroups with BCFI were assessed using Cox proportional hazards models, stratified by cohort (as defined by trial and chemotherapy use) and treatment assignment; the predictive value of those subgroups in terms of relative treatment effects was assessed by test for treatment-by-marker interaction. Subgroups were pre-defined based on prior St. Gallen Consensus statements [7, 8] as follows: ER \ 50 % versus C50 % with ER \ 10 % as an additional category in descriptive analyses; PgR \ 20 % versus 20-49 % versus C50 % with PgR \ 10 % as an additional category in descriptive analyses; and Ki-67 \ 14 % versus 14-19 % versus 20-25 % versus C26 % with the fourth category being data-driven corresponding to the upper 20th percentile of the distribution. Luminal A-like and B-like disease were defined according to the 2013 St. Gallen Consensus definition [8] in HER2-negative disease as follows: Luminal A-like if PgR C 20 % and Ki-67 \ 20 %; B-like if either PgR \ 20 % or Ki-67 C 20 % (or both). The assessment of clinical utility of markers according to quantitative level of expression used the non-parametric sliding-window subpopulation treatment effect pattern plot (STEPP) methodology [9, 10] for exploring treatment-covariate interaction with a continuous covariate. Separately for each of the four cohorts, STEPP investigated patterns in absolute treatment effects, as measured by Kaplan-Meier estimates of 5-year BCFI, across the continuum of centrally determined levels of ER, PgR, and Ki-67 expressions, using permutation testing of treatment-by-marker interaction. The median follow-up was 6 years in TEXT and 5.6 years in SOFT.
Results
The IBCSG Central Pathology Office reviewed invasive tumor material of 4818 (84 %) representative patients of 5707 patients in the intention-to-treat trial populations (Table S1 ). The analysis population was limited to 4115 patients with hormone receptor(HR)-positive, HER2-negative tumors (HR?/HER2-) after excluding 65 patients whose tumors were not confirmed to express some ER and/or PgR and 638 patients with HER2? tumors ( Figure S1 ). Characteristics of the 4115-patient HR?/HER2-analysis population according to cohort, as defined by trial and chemotherapy use, are summarized in Table 1 . The 5-year BCFI was 90.7 % overall (402 of 4115 patients had breast cancer events).
In this HR?/HER2-population, centrally determined ER expression was C50 % immunostained cells for 96 % of tumors, of which the majority had ER expression C90 % immunostained cells (Table 1 ; Figure S2 ). Investigation of the predictive value of ER expression level was therefore not feasible.
The median values of PgR and Ki-67 expressions were 90 and 18 % immunostained cells, respectively. As expected, the distribution of PgR was shifted lower, and that of Ki-67 was shifted higher, among the cohorts of patients who received 
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chemotherapy than among the cohorts that did not (Table 1) . According to the 2013 St. Gallen Consensus definitions of luminal A-like and B-like disease [8] , 41 % of patients overall had HER2-luminal B-like disease, including 25, 34, 55, and 49 % of patients in the SOFT no chemotherapy, TEXT no chemotherapy, TEXT chemotherapy, and SOFT prior chemotherapy cohorts, respectively. Lower tumor expression of ER and of PgR and higher expression of Ki-67 were associated with shorter BCFI (each P \ 0.001). Figure 1 illustrates the relation with BCFI in the overall HR?/HER2-population without regard to treatment assignment, according to marker subgroups and according to continuous levels of ER, PgR, and Ki-67 expression. Consistent with the individual markers, luminal B-like status was associated with shorter BCFI (P \ 0.001; Fig. 2 ).
PgR expression
There was no evidence of heterogeneity of the relative treatment effects according to pre-defined subgroups of PgR expression (each P [ 0.10 for PgR-by-treatment interaction; Table 2 ), indicating that PgR is not a predictive marker for these treatments. In STEPP analyses of absolute treatment effects in each of the four cohorts, improvements in 5-year BCFI with exemestane ? OFS versus tamoxifen ? OFS or versus tamoxifen alone appeared greater in subpopulations at the lowest PgR expression levels (in the range of 7-17 percentage points) than at higher PgR expression levels. In the two no chemotherapy cohorts (Fig. 3a, b) , the patterns suggested larger absolute improvement in 5-year BCFI with exemestane ? OFS versus tamoxifen ? OFS in TEXT or versus tamoxifen alone in SOFT at low PgR that disappeared at high PgR expression levels. A similar pattern was observed in the SOFT cohort who received prior chemotherapy; there was no evident pattern for the benefit of tamoxifen ? OFS versus tamoxifen across the range of PgR expression (Fig. 3d) . In the TEXT chemotherapy cohort, there was absolute benefit from exemestane ? OFS for 5-year BCFI in the TEXT chemotherapy cohort across all PgR expression levels (Fig. 3c) .
Ki-67 expression
There was no evidence of heterogeneity of the relative treatment effects according to pre-defined subgroups of Ki-67 expression (each P [ 0.10 for Ki-67-by-treatment interaction; Table 2 ), indicating that Ki-67 is not a predictive marker for these treatments. In STEPP analysis of 5-year BCFI according to level of Ki-67 expression, no pattern was evident in the SOFT no chemotherapy cohort (Fig. 4a) . Among TEXT patients, who all received OFS from the start of adjuvant therapy, the STEPPs revealed large absolute benefits of exemestane ? OFS versus tamoxifen ? OFS as subpopulation median values approached and surpassed 20 % Ki-67 expression (in the range from 4 to 14 percentage points), not evident at lower expression levels where 5-year BCFI was near 100 % (Fig. 4b, c) . Among SOFT patients who received prior chemotherapy, the 5-year BCFI benefit of exemestane ? OFS over tamoxifen (or tamoxifen ? OFS) was also apparent at higher levels of Ki-67 expression (in the range from 7 to 12 percentage points), but without evident pattern for tamoxifen ? OFS versus tamoxifen (Fig. 4d) .
St. Gallen luminal A/B-like (HER22) categories
The relative treatment benefit of exemestane ? OFS versus tamoxifen ? OFS in TEXT and versus tamoxifen alone in SOFT was evident in both luminal subgroups (Table 2 ; Fig. 5 ). The absolute differences in 5-year BCFI among patients with luminal A-like tumors varied but were quite small in most cohorts (1.5 and 1.9 % versus tamoxifen ? OFS at 5 years in TEXT no chemotherapy and chemotherapy cohorts, respectively; 0.8 and 3.6 % versus tamoxifen in SOFT no chemotherapy and prior chemotherapy cohorts, respectively). In the luminal B-like subgroup, there were larger absolute benefits of exemestane ? OFS versus tamoxifen with or without OFS in each of the cohorts (7.9 and 10.7 % vs. tamoxifen ? OFS at 5 years in TEXT no chemotherapy and chemotherapy cohorts, respectively; 1.5 and 7.1 % versus tamoxifen in SOFT no chemotherapy and prior chemotherapy cohorts, respectively).
Discussion
The TEXT and SOFT trials demonstrated that, on average for premenopausal women with HR? early breast cancer, adjuvant treatment with exemestane ? OFS provides superior outcomes relative to tamoxifen with or without OFS [2, 3] . SOFT also demonstrated that women who remain premenopausal after chemotherapy benefit from the addition of OFS to tamoxifen, and that tamoxifen alone remains an appropriate treatment for some premenopausal women at low risk of recurrence [2, 3] . Based upon centrally assessed expression of PgR and Ki-67, whether considering continuous expression levels or defining luminal A/B-like disease, it was apparent that patients with tumors having low PgR and/or high Ki-67 have the potential for larger absolute benefit of exemestane ? OFS versus tamoxifen ? OFS or tamoxifen alone because low PgR and high Ki-67 are associated with increased risk for recurrence. However, PgR and Ki-67 are not predictive markers of relative treatment efficacy and individually are not adequate for treatment selection for premenopausal women with HR?/HER2-disease. We hypothesized that premenopausal patients whose HER2-tumors had lower expression of PgR would have greater relative benefit of exemestane ? OFS versus tamoxifen with or without OFS, and of the addition of OFS to tamoxifen, than would patients with tumors having high PgR expression. This was not observed. The predictive role of PgR for adjuvant therapy selection among premenopausal and postmenopausal women may differ. Earlier IBCSG studies observed a predictive value of PgR for efficacy of chemo-endocrine versus endocrine therapy [11] 
Cox models were stratified by nodal status and chemotherapy use. The Wald v 2 tests for marker-by-treatment interaction had 2, 3, or 1 degree of freedom for PgR, Ki-67, and luminal A/B-like, respectively. HRs (CI) for undetermined marker values omitted, e.g., for luminal A/B-like T ? OFS versus Tam, this is why the two HRs are both greater than the overall HR OFS Ovarian function suppression, T or Tam tamoxifen, E exemestane, HR hazard ratio, PgR progesterone receptor and for response to perioperative chemotherapy [12] in node-negative disease for premenopausal but not postmenopausal women. A predictive value of PgR for efficacy of tamoxifen versus no endocrine therapy in ER? disease also has been suggested in premenopausal women [13] , in contrast to results of the Early Breast Cancer Trialists Collaborative Group (EBCTCG) overview which included predominantly postmenopausal patients [14] . For the efficacy of an AI versus tamoxifen in postmenopausal women with HR? disease, low PgR expression was not predictive of the relative efficacy of AIs versus tamoxifen [5, 15, 16] , nor of the absolute benefit in the BIG 1-98 trial [5] . Downregulation of PgR in postmenopausal women's tumors might reflect ER activity due to low levels of circulating estrogen, in which case a differential activity of tamoxifen versus AI might not be seen. In premenopausal women, down-regulation of PgR is likely due to the (co-)activation of growth factor receptor pathways, possibly via activation of non-genomic membrane ER. It has been reported that both estrogens and tamoxifen, but not AIs, can activate or sustain growth factor receptors pathways [17] , and hence the beneficial effects of tamoxifen could be reduced as compared to AIs in this scenario. However, among the premenopausal patients in TEXT and SOFT, there was no evidence of heterogeneity of the relative treatment effects according to PgR expression level. In three of the four cohorts-those without chemotherapy or with prior chemotherapy-the homogeneous relative treatment effect of this prognostic marker translated into a heterogeneous absolute treatment effect. A pattern of larger, clinically meaningful absolute improvement in 5-year BCFI from exemestane ? OFS versus tamoxifen, with or without OFS, was apparent among patients with tumors having lower PgR levels than among those with high PgR expression levels.
Very high Ki-67 expression was hypothesized to be predictive of larger relative and absolute benefit of exemestane ? OFS versus tamoxifen with or without OFS. This was previously observed among postmenopausal women randomized to letrozole versus tamoxifen in the BIG 1-98 trial, without regard to HER2 status [4] . A large absolute benefit of exemestane ? OFS versus tamoxifen, with or without OFS, at high levels of Ki-67 that diminished at low levels of Ki-67 was apparent in the TEXT [18] . In the analysis population, only 57 of 4115 tumors had this combination of expression levels, and thus we could not contrast these two definitions in terms of prognosis or predictive value for endocrine therapy in premenopausal women with HER2-disease. Our data do also suggest that further refinements of the definitions may improve clinical utility, for example, exploring thresholds of PgR separately according to HER2-status or in a HR?, HER2-negative population.
TEXT and SOFT could not inform the use of the ER expression level to select treatment for HER2-disease, because the vast majority of patients' tumors had ER expression C90 %. This is not unexpected considering the bimodal pattern of ER expression [19] and the trial eligibility requiring ER and/or PgR C 10 % cells by local testing. With longer follow-up, more observed recurrences may provide insight. The investigation was limited to patients with HER2-disease because adjuvant trastuzumab with chemotherapy is indicated for most patients with HER2? disease, and this subgroup was the exception for which there was an evidence of treatment effect heterogeneity that requires further investigation [2, 3] .
The TEXT and SOFT premenopausal populations with HR?/HER2-disease do not suggest heterogeneous relative treatment efficacy according to the level of PgR and Ki-67 expression as assessed in a central laboratory, nor according to luminal A/B-like status. Tumors having low PgR and/or high Ki-67 have worse prognosis and thus potential for larger absolute benefit of exemestane ? OFS versus tamoxifen ? OFS or tamoxifen alone, but these markers individually are not adequate for treatment decision-making for premenopausal women with HR?/ HER2-disease. 
